Technologies
Muscular
Histone deacetylases (HDACs) mediate regulation of gene expression via changes in nucleosome conformation. Dysregulation of histone acetylation, involving CBP, a neuroprotective transcription factor with histone acetyltransferase activity, has been found in Huntington’s disease (HD), Alzheimer’s disease (AD), and Rubinstein-Taybi syndrome. In a cellular model of AD, cell death was accompanied by loss of CBP function and histone deacetylation.
Histone deacetylases (HDACs) mediate regulation of gene expression via changes in nucleosome conformation. Dysregulation of histone acetylation, involving CBP, a neuroprotective transcription factor with histone acetyltransferase activity, has been found in Huntington’s disease (HD), Alzheimer’s disease (AD), and Rubinstein-Taybi syndrome. In a cellular model of AD, cell death was accompanied by loss of CBP function and histone deacetylation.
Below the knee muscle weakness, defined by weak
dorsiflexor (shin) or plantarflexor (calf) muscle groups, can result from a
variety of physical impairments or congenital abnormalities. Stroke, spinal
cord injuries, polio and multiple sclerosis are among some of the physical injuries
and congenital defects responsible for the condition. The largest complication
from below the knee muscle weakness is abnormal gait, which when compensated
for can lead to further complications in other muscles and joints.
This
technology is a novel, untethered, powered, ankle-foot-orthosis (AFO) design
that controls and assists ankle motion using plantarflexor and dorsiflexor
torque at the ankle joint. This device is called a Portable-Powered-Ankle-Foot-Orthosis
(PPAFO), and utilizes fluid-powered actuators to provide active ankle torque
assistance during gait. The system is self-contained and uses a portable
pneumatic and/or hydraulic power source and embedded electronics to power and
control the actuation of the foot.
Glucagon-like peptide-1 (GLP-1) is a 30-mer peptide hormone secreted by intestinal L-cells that bind to GLP-1 receptor on the β-cell and stimulates insulin secretion in response to ingested carbohydrates and lipids. Native GLP-1 peptide, however, has limited applications as a therapeutic agent due to its rapid elimination in vivo. A number of GLP-1 analogs with longer half-lives have been synthesized and approved for treatment. The aqueous solubility of the peptide is low.
All cells respond to chemical and physical cues form their environment to program their gene regulat
This invention is an improved process for three-dimensional cardiac magnetic resonance imaging (MRI), designed to overcome the limitations of current MRI systems in imaging dynamic phenomena such as the beating heart, flow of contrast agents in blood vessels, brain excitation, or joint movement.
This invention produces motion movies of the beating heart, and other dynamic phenomena, with significantly higher spatial and temporal resolution than currently feasible.